Connection

M ATASSI to Botulinum Toxins, Type A

This is a "connection" page, showing publications M ATASSI has written about Botulinum Toxins, Type A.
Connection Strength

9.672
  1. The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
    View in: PubMed
    Score: 0.464
  2. Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. Immunol Lett. 2017 10; 190:257-264.
    View in: PubMed
    Score: 0.461
  3. Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules. J Neuroimmunol. 2017 05 15; 306:31-39.
    View in: PubMed
    Score: 0.446
  4. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
    View in: PubMed
    Score: 0.434
  5. Effects of membrane properties on the binding activities of the HN and HC heavy-chain domains of botulinum neurotoxin A. Biochim Biophys Acta. 2016 12; 1864(12):1678-1685.
    View in: PubMed
    Score: 0.432
  6. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.410
  7. Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Sci Rep. 2015 Oct 28; 5:15776.
    View in: PubMed
    Score: 0.407
  8. Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin. Immunobiology. 2014 Dec; 219(12):950-7.
    View in: PubMed
    Score: 0.374
  9. Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates. J Neuroimmunol. 2014 Jul 15; 272(1-2):29-34.
    View in: PubMed
    Score: 0.368
  10. Inhibition in?vivo of the activity of botulinum neurotoxin A by small molecules selected by virtual screening. Toxicon. 2012 Nov; 60(6):1180-90.
    View in: PubMed
    Score: 0.326
  11. Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A. Immunol Lett. 2012 Feb 29; 142(1-2):20-7.
    View in: PubMed
    Score: 0.310
  12. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.310
  13. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains. Immunobiology. 2012 Jan; 217(1):1-7.
    View in: PubMed
    Score: 0.306
  14. Does Clostridium botulinum neurotoxin A exhibit molecular mimicry with thyroid autoantigens and cause thyroid complications in predisposed persons? Endocrine. 2011 Aug; 40(1):140-1; author reply 142-3.
    View in: PubMed
    Score: 0.304
  15. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.302
  16. Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates. Immunol Lett. 2011 Jun 30; 137(1-2):46-52.
    View in: PubMed
    Score: 0.294
  17. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011 Jul; 216(7):782-92.
    View in: PubMed
    Score: 0.291
  18. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin. Immunobiology. 2011 Jun; 216(6):698-706.
    View in: PubMed
    Score: 0.288
  19. Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions. Protein J. 2010 Jul; 29(5):320-7.
    View in: PubMed
    Score: 0.282
  20. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
    View in: PubMed
    Score: 0.249
  21. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
    View in: PubMed
    Score: 0.221
  22. Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action. Crit Rev Immunol. 2007; 27(4):319-41.
    View in: PubMed
    Score: 0.221
  23. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
    View in: PubMed
    Score: 0.211
  24. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: a new assay for blocking and non-blocking antibodies. J Neurosci Methods. 2006 Mar 15; 151(2):90-6.
    View in: PubMed
    Score: 0.208
  25. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A. Mol Immunol. 2005 Aug; 42(12):1509-20.
    View in: PubMed
    Score: 0.195
  26. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains. Immunol Invest. 2005; 34(2):119-42.
    View in: PubMed
    Score: 0.192
  27. Mapping of the synaptosome-binding regions on the heavy chain of botulinum neurotoxin A by synthetic overlapping peptides encompassing the entire chain. Protein J. 2004 Nov; 23(8):539-52.
    View in: PubMed
    Score: 0.190
  28. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J. 2004 Jan; 23(1):39-52.
    View in: PubMed
    Score: 0.179
  29. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
    View in: PubMed
    Score: 0.163
  30. Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol Lett. 1998 Jan; 60(1):7-12.
    View in: PubMed
    Score: 0.118
  31. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin. Mol Immunol. 1997 Oct; 34(14):1031-40.
    View in: PubMed
    Score: 0.116
  32. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol Invest. 1997 Jun; 26(4):491-504.
    View in: PubMed
    Score: 0.114
  33. Synaptotagmin II and gangliosides bind independently with botulinum neurotoxin B but each restrains the other. Protein J. 2014 Jun; 33(3):278-88.
    View in: PubMed
    Score: 0.092
  34. Location of the synaptosome-binding regions on botulinum neurotoxin B. Biochemistry. 2012 Jan 10; 51(1):316-28.
    View in: PubMed
    Score: 0.078
  35. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
    View in: PubMed
    Score: 0.076
  36. The binding sites on botulinum neurotoxin B for synaptotagmin and for blocking antibodies. Biochem Biophys Res Commun. 2008 Nov 21; 376(3):631-2.
    View in: PubMed
    Score: 0.062
  37. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
    View in: PubMed
    Score: 0.062
  38. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin. Mol Immunol. 2008 Feb; 45(4):910-24.
    View in: PubMed
    Score: 0.058
  39. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.